Skip to main content
Fig. 4 | Journal of Nanobiotechnology

Fig. 4

From: Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment

Fig. 4

Biosafety evaluation of HSA-ATO NPs. a The relative accumulation quality of atovaquone in major organs and tumor sits was analyzed by HPLC. The weight of liver (b) and kidney (c) of the indicated mice with 7-day administration (n = 5). d The representative images of H&E-stained liver and kidney sections in mice with the indicated treatments. Scale bar: 500 μm. e The levels of alanine transaminase (ALT), aspartate aminotransferase (AST), serum creatinine (CRE) and blood urea nitrogen (BUN) were analyzed by ELISA assay. Data are presented as mean ± SD. ***, P < 0.001

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us